425 related articles for article (PubMed ID: 32346095)
1. Immunomodulation by anticancer cell cycle inhibitors.
Petroni G; Formenti SC; Chen-Kiang S; Galluzzi L
Nat Rev Immunol; 2020 Nov; 20(11):669-679. PubMed ID: 32346095
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
4. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Tripathy D; Bardia A; Sellers WR
Clin Cancer Res; 2017 Jul; 23(13):3251-3262. PubMed ID: 28351928
[TBL] [Abstract][Full Text] [Related]
6. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.
Mills CC; Kolb EA; Sampson VB
Cancer Res; 2017 Dec; 77(23):6489-6498. PubMed ID: 29097609
[TBL] [Abstract][Full Text] [Related]
8. Targeting CDK4 and CDK6: From Discovery to Therapy.
Sherr CJ; Beach D; Shapiro GI
Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
[TBL] [Abstract][Full Text] [Related]
9. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications.
Yousuf M; Alam M; Shamsi A; Khan P; Hasan GM; Rizwanul Haque QM; Hassan MI
Int J Biol Macromol; 2022 Oct; 218():394-408. PubMed ID: 35878668
[TBL] [Abstract][Full Text] [Related]
11. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
12. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
14. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
15. Cell-Cycle Therapeutics Come of Age.
Ingham M; Schwartz GK
J Clin Oncol; 2017 Sep; 35(25):2949-2959. PubMed ID: 28580868
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
17. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Spring LM; Wander SA; Andre F; Moy B; Turner NC; Bardia A
Lancet; 2020 Mar; 395(10226):817-827. PubMed ID: 32145796
[TBL] [Abstract][Full Text] [Related]
19. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
20. The transcriptome of CDK4/6 inhibition.
Knudsen ES; Witkiewicz AK
Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
[No Abstract] [Full Text] [Related]
[Next] [New Search]